IMPACCT Real-World Evidence Summit on October 27-29, 2025 in Boston, United States

As the CMS introduces new guidance for RWD studies, the FDA announces a RWE Center to promote its use in regulatory decision-making, and RWD becomes more accessible, investment is pouring into RWE generation. It is evident RWE will play an increasingly pivotal role in the drug development lifecycle, but questions still remain for the experts optimizing and applying RWE.

As the only industry meeting uniting RWE experts, the 13th IMPACCT Real-World Evidence Summit offers you the unique opportunity to consolidate, innovate and optimize your RWE strategy at all stages of the drug development lifecycle.

Connect with 140+ industry pioneers from Pfizer, AstraZeneca, Alexion, Moderna, and Boehringer Ingelheim, as they share first-hand case studies in fortifying data quality, validating use of AI and predictive modeling in data analysis, leveraging RWE to support regulatory submissions and more.

URLs:

Tickets: https://go.evvnt.com/3095728-0?pid=10008

Brochure: https://go.evvnt.com/3095728-3?pid=10008

Time: 9:00 AM - 4:45 PM

Prices:

Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day: USD 4197.00,

Drug Developer Pricing - 2 Day Pass (Conference Only) : USD 2999.00,

Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 3597.00,

Academic Pricing - 2 Day Pass (Conference Only): USD 2599.00,

Solution Provider Pricing - 3 Day Pass (Conference + Workshop Day): USD 5197.00,

Solution Provider Pricing - 2 Day Pass (Conference Only): USD 3799.00

Speakers: Alan Bajramovic, Information and Real-World Data Strategist, Abbvie, Alexander Cole, Executive Director and Head of Epidemiology and Real-World Science, Alexion Pharmaceuticals, Amadeo Salvador, Senior Scientist - Data, Abbvie, Amanda Bruno, Vice President, Evidence Planning and Execution, Abbvie, Claire Zhao, Director and Group Lead - Artificial Intelligence, Machine Learning, Quantitative and Digital Sciences, Pfizer, Eugean Jiwanmall, Senior Research Analyst for Medical Policy and Technology Evaluation, Independence Blue Cross, Hairong Xu, Executive Director - Global Medical Affairs and Clinical Development, Kite Pharma Inc, Jason Zhu, Associate Director - Real-World Data Engineer, AstraZeneca, Javeria Khalid, Teaching and Research Assistant, University of Houston, Joseph Cappelleri, Executive Director of Biostatistics and Head of Health Economics Outcomes Research, Pfizer, Kathleen Villa, Executive Director - Global Evidence Generation, Ionis / Akcea, Kelly Zou, Head of Global Medical Analytics and Real-World Evidence, Viatris Korea, Kimberly Barnholt, Executive Generation, US Medical Affairs, Genentech, Leah Sansbury, Senior Director - Epidemiology and Oncology, Moderna, Mohsin Shah, Associate Director - Global Integrated Evidence, Epidemiology and Real-World Evidence Oncology, Boehringer Ingelheim, Monica McClain, Director, Medical Evidence Generation, Ionis Pharmaceuticals, Inc., Nicholas Everage, Senior Director and Head of Epidemiology, Biogen, Patricia Dorling, Senior Director - Value and Implementation Outcomes Research and Oncology, Merck and Co, Rahul Shenolikar, Global Real-World Evidence Strategy Lead, Lung Cancer, AstraZeneca, Rhys Williams, Vice President - Integrative Evidence Generation, Health Economics and Global Medical Affairs, BeiGene, Rikisha Gupta, Director - Real-World Evidence, Gilead Sciences, Rongrong Wang, Principal Data Scientist, Genentech, Sarah Small, Director - Health Experience Development, Otsuka Precision Health, Inc, Simon Dagenais, Senior Director - Real-World Evidence, Pfizer, Stephania Pirondi, Head of Global Clinical Project Management Unit, Chiesi Farmaceutici, Steve Gao, Executive Director and Head, Real-World Evidence Inflammation, Gilead Sciences, Supriya Kumar, Senior Director, Real-World Data Office, AstraZeneca, Tom Dougherty, RWE Strategy Lead, Novo Nordisk, Vanja Sikirica, Executive Director - Epidemiology, Health Economics Outcomes Research and Patient Centered Outcomes, Moderna